Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: Interleukin-15 vs. interleukin-2

Yuh Min Chen, Chou Chik Ting, Jacqueline Whang Peng, Wen Kuang Yang, Kuang Yao Yang, Chun Ming Tsai, Reury Perng Perng

研究成果: 雜誌貢獻文章

22 引文 (Scopus)

摘要

The present study attempts to define the role of interleukin-15 (IL-15), as compared with IL-2, in generating cytotoxic T lymphocytes (CTL) from the malignant effusions of cancer patients. Effusion-associated lymphocytes (EAL) from malignant effusion were incubated with IL-15 or IL-2 with or without αCD3. Proliferation and cytotoxicity assays were performed. IL-15 was found to have at least an equivalent, if not higher, activity to IL-2 in terms of lymphocyte proliferation and generation of CTL from EAL. The proliferative response of EAL, cocultured with IL-15, with or without αCD3, was partly inhibited by pretreatment with an anti-IL-2 receptor β chain monoclonal antibody (mAb). The proliferative response of EAL, cocultured with αCD3, IL- 2, or both, was partly inhibited by pretreatment with an anti-IL-2 receptor α chain mAb. Overnight [51Cr] release assays against K562, Daudi, and the patients' autologous tumor cells were done to evaluate EAL's cytolytic activity. MHC class I Ab blocked the stimulated cytolytic activity of EAL against autologous tumors. An mAb depletion assay showed that the phenotype of the restored EAL was CD16-CD4-CD8+; thus, the restored activity of EAL was CTL activity. The results suggest that both IL-15 and IL-2 can restore CTL activity from EAL in the presence of T cell receptor (TCR)-CD3 engagement, but the effect of IL-15 was superior.
原文英語
頁(從 - 到)31-39
頁數9
期刊Journal of Interferon and Cytokine Research
20
發行號1
DOIs
出版狀態已發佈 - 二月 7 2000
對外發佈Yes

指紋

Malignant Pleural Effusion
Interleukin-15
Cytotoxic T-Lymphocytes
Interleukin-2
Lymphocytes
Interleukin-2 Receptors
Monoclonal Antibodies
Neoplasms
T-Cell Antigen Receptor
Phenotype

ASJC Scopus subject areas

  • Immunology
  • Cell Biology
  • Virology

引用此文

Restoration of cytotoxic T lymphocyte function in malignant pleural effusion : Interleukin-15 vs. interleukin-2. / Chen, Yuh Min; Ting, Chou Chik; Whang Peng, Jacqueline; Yang, Wen Kuang; Yang, Kuang Yao; Tsai, Chun Ming; Perng, Reury Perng.

於: Journal of Interferon and Cytokine Research, 卷 20, 編號 1, 07.02.2000, p. 31-39.

研究成果: 雜誌貢獻文章

Chen, Yuh Min ; Ting, Chou Chik ; Whang Peng, Jacqueline ; Yang, Wen Kuang ; Yang, Kuang Yao ; Tsai, Chun Ming ; Perng, Reury Perng. / Restoration of cytotoxic T lymphocyte function in malignant pleural effusion : Interleukin-15 vs. interleukin-2. 於: Journal of Interferon and Cytokine Research. 2000 ; 卷 20, 編號 1. 頁 31-39.
@article{2f2fd76647de4054a46defad8d7e8418,
title = "Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: Interleukin-15 vs. interleukin-2",
abstract = "The present study attempts to define the role of interleukin-15 (IL-15), as compared with IL-2, in generating cytotoxic T lymphocytes (CTL) from the malignant effusions of cancer patients. Effusion-associated lymphocytes (EAL) from malignant effusion were incubated with IL-15 or IL-2 with or without αCD3. Proliferation and cytotoxicity assays were performed. IL-15 was found to have at least an equivalent, if not higher, activity to IL-2 in terms of lymphocyte proliferation and generation of CTL from EAL. The proliferative response of EAL, cocultured with IL-15, with or without αCD3, was partly inhibited by pretreatment with an anti-IL-2 receptor β chain monoclonal antibody (mAb). The proliferative response of EAL, cocultured with αCD3, IL- 2, or both, was partly inhibited by pretreatment with an anti-IL-2 receptor α chain mAb. Overnight [51Cr] release assays against K562, Daudi, and the patients' autologous tumor cells were done to evaluate EAL's cytolytic activity. MHC class I Ab blocked the stimulated cytolytic activity of EAL against autologous tumors. An mAb depletion assay showed that the phenotype of the restored EAL was CD16-CD4-CD8+; thus, the restored activity of EAL was CTL activity. The results suggest that both IL-15 and IL-2 can restore CTL activity from EAL in the presence of T cell receptor (TCR)-CD3 engagement, but the effect of IL-15 was superior.",
author = "Chen, {Yuh Min} and Ting, {Chou Chik} and {Whang Peng}, Jacqueline and Yang, {Wen Kuang} and Yang, {Kuang Yao} and Tsai, {Chun Ming} and Perng, {Reury Perng}",
year = "2000",
month = "2",
day = "7",
doi = "10.1089/107999000312711",
language = "English",
volume = "20",
pages = "31--39",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Restoration of cytotoxic T lymphocyte function in malignant pleural effusion

T2 - Interleukin-15 vs. interleukin-2

AU - Chen, Yuh Min

AU - Ting, Chou Chik

AU - Whang Peng, Jacqueline

AU - Yang, Wen Kuang

AU - Yang, Kuang Yao

AU - Tsai, Chun Ming

AU - Perng, Reury Perng

PY - 2000/2/7

Y1 - 2000/2/7

N2 - The present study attempts to define the role of interleukin-15 (IL-15), as compared with IL-2, in generating cytotoxic T lymphocytes (CTL) from the malignant effusions of cancer patients. Effusion-associated lymphocytes (EAL) from malignant effusion were incubated with IL-15 or IL-2 with or without αCD3. Proliferation and cytotoxicity assays were performed. IL-15 was found to have at least an equivalent, if not higher, activity to IL-2 in terms of lymphocyte proliferation and generation of CTL from EAL. The proliferative response of EAL, cocultured with IL-15, with or without αCD3, was partly inhibited by pretreatment with an anti-IL-2 receptor β chain monoclonal antibody (mAb). The proliferative response of EAL, cocultured with αCD3, IL- 2, or both, was partly inhibited by pretreatment with an anti-IL-2 receptor α chain mAb. Overnight [51Cr] release assays against K562, Daudi, and the patients' autologous tumor cells were done to evaluate EAL's cytolytic activity. MHC class I Ab blocked the stimulated cytolytic activity of EAL against autologous tumors. An mAb depletion assay showed that the phenotype of the restored EAL was CD16-CD4-CD8+; thus, the restored activity of EAL was CTL activity. The results suggest that both IL-15 and IL-2 can restore CTL activity from EAL in the presence of T cell receptor (TCR)-CD3 engagement, but the effect of IL-15 was superior.

AB - The present study attempts to define the role of interleukin-15 (IL-15), as compared with IL-2, in generating cytotoxic T lymphocytes (CTL) from the malignant effusions of cancer patients. Effusion-associated lymphocytes (EAL) from malignant effusion were incubated with IL-15 or IL-2 with or without αCD3. Proliferation and cytotoxicity assays were performed. IL-15 was found to have at least an equivalent, if not higher, activity to IL-2 in terms of lymphocyte proliferation and generation of CTL from EAL. The proliferative response of EAL, cocultured with IL-15, with or without αCD3, was partly inhibited by pretreatment with an anti-IL-2 receptor β chain monoclonal antibody (mAb). The proliferative response of EAL, cocultured with αCD3, IL- 2, or both, was partly inhibited by pretreatment with an anti-IL-2 receptor α chain mAb. Overnight [51Cr] release assays against K562, Daudi, and the patients' autologous tumor cells were done to evaluate EAL's cytolytic activity. MHC class I Ab blocked the stimulated cytolytic activity of EAL against autologous tumors. An mAb depletion assay showed that the phenotype of the restored EAL was CD16-CD4-CD8+; thus, the restored activity of EAL was CTL activity. The results suggest that both IL-15 and IL-2 can restore CTL activity from EAL in the presence of T cell receptor (TCR)-CD3 engagement, but the effect of IL-15 was superior.

UR - http://www.scopus.com/inward/record.url?scp=0033969272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033969272&partnerID=8YFLogxK

U2 - 10.1089/107999000312711

DO - 10.1089/107999000312711

M3 - Article

C2 - 10670650

AN - SCOPUS:0033969272

VL - 20

SP - 31

EP - 39

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 1

ER -